BioCryst Pharma (BCRX) PT Raised to $15 at Jefferies

Jefferies analyst Maury Raycroft raised the price target on BioCryst Pharma (NASDAQ: BCRX) to $15.00 (from $14.00) while maintaining a Buy rating.

The analyst comments "BCRX to acquire ATXS for $13/sh at +53% premium to yesterday's close for long-acting (Q3M/Q6M) HAE drug navenibart for total equity value of $920M. Transaction has been approved by both cos BODs and expected to close 1Q26. Naven top-line ph.III data are expected early'27. BCRX believes they can reach +15% CAGR in Orladeyo+naven sales over the next decade to get est $1.8B+ by 2033 w/ $1B+ cash by 2029. We added naven to our model (50% POS). PT to $15."

You May Also Be Interested In

• BofA Securities Upgrades Moderna (MRNA) to Neutral
• Palo Alto Networks (PANW) PT Raised to $390 at UBS, Neutral Rating Maintained
• Morgan Stanley Upgrades Suncor Energy (SU) to Overweight